The purpose of this study is to observationally evaluate the efficacy and safety data of Relmacabtagene Autoleucel for the treatment of patients with hematologic malignancies for up to 15 years after infusion. The treating physician will determine the most appropriate diagnostic and therapeutic regimen for the patient based on clinical practice. No therapeutic intervention will be administered to patients in this study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Signed informed consent
2. Patients who have been treated with Relma-cel, including those who have received off-label products;
3. If previously enrolled in another clinical study, they must have completed follow-up in the previous study, or have withdrawn or lost follow-up in the previous study.
You may not be if
1.Patients who have been treated with Relma-cel and then have been treated with other CAR-T products.
Clareo Health | Relmacabtagene Autoleucel in Hematologic Malignancies
